GenomicsNext is a hybrid capture, comprehensive ctDNA profiling platform combining genomic alterations and inferred gene expression from a single sample.

By defining DNA fragmentation patterns in blood, GenomicsNext allows a single, comprehensive genomic-profiling hybrid-capture platform to deliver alterations (i.e., SNVs, Indels, CNVs, fusions, MSI, TMB), as well as expression-based traits such as expression of specific high-value targets (e.g., HER2, ER, etc.), intrinsic subtypes, predictive and prognostic gene expression signatures, and novel biomarkers.

Established and future applications of GenomicsNext include:

• ctDNA alteration testing (i.e., SNVs, Indels, CNVs, fusions, MSI, TMB)
• Companion diagnostics for expression-driven therapies (e.g., ADC targets)
• Algorithms for
  • tissue of origin
  • subtypes
  • proliferation status
  • tumor fraction
  • germline/somatic origin
  • primary/metastatic origin
• Gene expression signatures
• Multimodal MRD, screening, and resistance monitoring
• Biomarker discovery using expression-like data matrices
• Novel variant-expression associations

Because gene alteration and fragmentomics information are complementary, the second dimension added by DNA fragment profiling enables DNA sequencing to extend across a full range of liquid biopsy applications – including many with unmet clinical need today.